Stockscreener 앱 받기
2.14
5.94%
0.12
전일 마감가:
$2.02
열려 있는:
$1.99
하루 거래량:
156.92K
Relative Volume:
0.54
시가총액:
$7.70M
수익:
-
순이익/손실:
$-15.47M
주가수익비율:
-4.28
EPS:
-0.5
순현금흐름:
$-13.51M
1주 성능:
+18.89%
1개월 성능:
-7.76%
6개월 성능:
+14.44%
1년 성능:
-72.31%
1일 변동 폭
$1.99
$2.18
1주일 범위
$1.71
$2.18
52주 변동 폭
$1.30
$8.20
Nls Pharmaceutics Ltd Stock (NLSP) Company Profile
NLSP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NLSP
Nls Pharmaceutics Ltd
|
2.14 | 9.28M | 0 | -15.47M | -13.51M | -0.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Nls Pharmaceutics Ltd 주식(NLSP)의 최신 뉴스
NLS Pharmaceutics Regains Compliance With Nasdaq Stockholders' Equity Requirement - 富途牛牛
What machine learning models say about NLS Pharmaceutics AG Equity WarrantStock Portfolio Risk and Return Analysis - Newser
Using data models to predict NLS Pharmaceutics AG stock movementFree Entry Alert With Low Drawdown Strategy - Newser
Is NLS Pharmaceutics AG Equity Warrant still worth holding after the dipForecasting Stock Moves with AI Insights - Newser
Can technical indicators confirm NLS Pharmaceutics AG’s reversalRSI and MACD Signal Summary with Trends - Newser
Developing predictive dashboards with NLS Pharmaceutics AG Equity Warrant dataFree Weekly Setup With 3x Return Potential - Newser
Building trade automation scripts for NLS Pharmaceutics AGFree Smart Trade Plans With Risk Protection - Newser
Can trapped investors hope for a rebound in NLS Pharmaceutics AGWeekly Growth Portfolio Performance Summary - Newser
NLS Pharmaceutics Enters Warrant Exchange Agreement with Alpha Capital - TipRanks
Custom watchlist performance reports with NLS Pharmaceutics AGFree Fundamental Winners With Safe Entry Plan - Newser
Analyzing NLS Pharmaceutics AG with multi timeframe chartsFree Early Entry Tips With Low Risk Zone - Newser
Can momentum traders help lift NLS Pharmaceutics AG Equity WarrantLow Risk Stock Trade Opportunity Analysis - Newser
Volume spikes in NLS Pharmaceutics AG stock – what they meanTrend Confirmation Scanner with Entry Focus - Newser
Why NLS Pharmaceutics AG stock attracts strong analyst attentionFree Early Entry Tips With Low Risk Zone - Newser
Does NLS Pharmaceutics AG Equity Warrant stock pay reliable dividendsFree Stock Market Watch With Alerts - Newser
How many analysts rate NLS Pharmaceutics AG as a “Buy”Achieve fast wealth growth with smart picks - Jammu Links News
What are the latest earnings results for NLS Pharmaceutics AGMassive wealth growth - Jammu Links News
How does NLS Pharmaceutics AG compare to its industry peersSky-high profits - Jammu Links News
NLS Pharmaceutics Announces Merger with Kadimastem and Secures $25 Million Financing Facility - AInvest
How does NLS Pharmaceutics AG Equity Warrant generate profit in a changing economyDaily Trading Alerts For Every Investor - Jammu Links News
Is This the Dip to Buy in NLS Pharmaceutics AGChart Breakout Buy Signal Detection Confirmed - beatles.ru
Institutional scanner results for NLS Pharmaceutics AG Equity WarrantAI Trend Detection for Entry Timing - Newser
How strong is NLS Pharmaceutics AG company’s balance sheetMarket Forecast Outlook With Proven Results - Jammu Links News
NLS Pharmaceutics AG Inches Above Key Support — Safe to HoldMarket Surge Signal for Swing Traders Triggered - metal.it
Can technical indicators confirm NLS Pharmaceutics AG Equity Warrant’s reversal - Newser
Will NLS Pharmaceutics AG Equity Warrant stock recover after recent dropSwing Entry Risk Mitigation with Chart Analysis - Newser
How NLS Pharmaceutics AG stock performs during market volatilityFree Triple Digit Return Stock Predictions - Newser
NLS Pharmaceutics (NASDAQ:NLSP) Shares Up 2% – Should You Buy? - Defense World
Sector Leaders Rotate Capital Into NLS Pharmaceutics AGProfit Focused Stock Screener Results Released - metal.it
Published on: 2025-07-28 23:38:35 - metal.it
Risk vs reward if holding onto NLS Pharmaceutics AG Equity WarrantShort-Term Market Movement Forecast Report - Newser
Does NLS Pharmaceutics AG Equity Warrant stock perform well during market downturnsConsistently high yield - Jammu Links News
What is the dividend policy of NLS Pharmaceutics AG stockGet timely alerts on market opportunities - Jammu Links News
What is the risk reward ratio of investing in NLS Pharmaceutics AG Equity Warrant stockAI Powered Tracker That Work - jammulinksnews.com
Is it the right time to buy NLS Pharmaceutics AG stockUnlock exclusive trading strategies for gains - Jammu Links News
Should I hold or sell NLS Pharmaceutics AG Equity Warrant stock in 2025Get daily updates on the hottest stocks - jammulinksnews.com
What makes NLS Pharmaceutics AG Equity Warrant stock price move sharplyInvest smarter with data-backed trading alerts - jammulinksnews.com
How volatile is NLS Pharmaceutics AG stock compared to the marketFastest return on investment - Jammu Links News
What drives NLS Pharmaceutics AG Equity Warrant stock priceFree Stock Movement Tracking - PrintWeekIndia
Is NLS Pharmaceutics AG a good long term investmentSky-high profits - PrintWeekIndia
What risks could impact NLS Pharmaceutics AG Equity Warrant stock performanceRapid Gain Targets - Newser
What drives NLS Pharmaceutics AG stock priceBreakout portfolio performance - jammulinksnews.com
What analysts say about NLS Pharmaceutics AG Equity Warrant stockTremendous growth opportunities - Autocar Professional
What analysts say about NLS Pharmaceutics AG stockExceptional portfolio growth - jammulinksnews.com
Is NLS Pharmaceutics AG Equity Warrant a good long term investmentPhenomenal capital gains - jammulinksnews.com
NLS Pharmaceutics Amends Merger Agreement with Kadimastem - TipRanks
NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy - The Malaysian Reserve
How NLS Pharmaceutics AG stock reacts to Fed policy changesCapital Protected Stock Selections - Newser
NLS Pharma's Diabetes Treatment Project Gets Fresh Funding Boost From US-Israel Foundation - 富途牛牛
Nls Pharmaceutics Ltd (NLSP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):